Evidence map›Paper›PMID 32522289›Full record

ArticleParasites & vectors2020

Amaryllidaceae alkaloids with anti-Trypanosoma cruzi activity.

Nieves Martinez-Peinado, Nuria Cortes-Serra, Laura Torras-Claveria, Maria-Jesus Pinazo, Joaquim Gascon, Jaume Bastida, Julio Alonso-Padilla

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Identification of novel compounds againstComputational and structural biotechnology journal · 2025
    Article
  7. Article
  8. The Antioxidant and Proapoptotic Effects ofPlants (Basel, Switzerland) · 2023
    Article
  9. Article
  10. Antiparasitic Activity ofMicroorganisms · 2023
    Article
  11. Review
  12. Article
  13. Article
  14. Identification of compounds with activity againstFrontiers in cellular and infection microbiology · 2022
    Article
  15. Article
  16. In Vitro Anti-Plants (Basel, Switzerland) · 2021
    Article
  17. Novel Purine Chemotypes with Activity againstPharmaceuticals (Basel, Switzerland) · 2021
    Article
  18. Article
  19. Identification ofMicroorganisms · 2021
    Article
  20. Anti-International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nieves Martinez-PeinadoBarcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, 08036, Barcelona, Spain.
Nuria Cortes-SerraBarcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, 08036, Barcelona, Spain.
Laura Torras-ClaveriaDepartament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l´Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.
Maria-Jesus PinazoBarcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, 08036, Barcelona, Spain.
Joaquim GasconBarcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, 08036, Barcelona, Spain.
Jaume BastidaDepartament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l´Alimentació, Universitat de Barcelona, 08028, Barcelona, Spain.
Julio Alonso-PadillaBarcelona Institute for Global Health (ISGlobal), Hospital Clínic - University of Barcelona, 08036, Barcelona, Spain. julio.a.padilla@isglobal.org.ORCID http://orcid.org/0000-0003-4466-7969
Barcelona Institute for Global Health · ESUniversitat de Barcelona · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR00924Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR604CYTED Ciencia y Tecnología para el Desarrollo 416RT0511Departament de Salut, Generalitat de Catalunya PERIS 2016-2010 SLT008/18/00132Instituto de Salud Carlos III RICET RD12/0018/0010Ministerio de Ciencia, Innovación y Universidades "Centro de Excelencia Severo Ochoa 2019-2023" CEX2018-000806-S
6 · The paper itself

Abstract

backgroundChagas disease, caused by the protozoan Trypanosoma cruzi, is a neglected disease that affects ~7 million people worldwide. Development of new drugs to treat the infection remains a priority since those currently available have frequent side effects and limited efficacy at the chronic stage. Natural products provide a pool of diversity structures to lead the chemical synthesis of novel molecules for this purpose. Herein we analyzed the anti-T. cruzi activity of nine alkaloids derived from plants of the family Amaryllidaceae.

methodsThe activity of each alkaloid was assessed by means of an anti-T. cruzi phenotypic assay. We further evaluated the compounds that inhibited parasite growth on two distinct cytotoxicity assays to discard those that were toxic to host cells and assure parasite selectivity.

resultsWe identified a single compound (hippeastrine) that was selectively active against the parasite yielding selectivity indexes of 12.7 and 35.2 against Vero and HepG2 cells, respectively. Moreover, it showed specific activity against the amastigote stage (IC

conclusionsResults reported here suggest that natural products are an interesting source of new compounds for the development of drugs against Chagas disease.

Indexed as

Amaryllidaceae AlkaloidsAnimalsChlorocebus aethiopsDrug Evaluation, PreclinicalHep G2 CellsHumansInhibitory Concentration 50PhytochemicalsTrypanocidal AgentsTrypanosoma cruziVero CellsAmaryllidaceae AlkaloidshippeastrinePhytochemicalsTrypanocidal AgentsAlkaloidsAmaryllidaceaeChagas diseaseCytotoxicityHippeastrinePhenotypic assaysTrypanosoma cruzi

Identifiers

PMID32522289
PMCPMC7288428
OpenAlexW3034024735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.